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ABSTRACT
Objective: Amlodipine besylate is a calcium channel blocker used in the treatment of hypertension which is practically insoluble in water. The present 
study aims to design oral fast-release tablets of amlodipine besylate and to optimize the dissolution of the drug by altering the carrier concentration.
Materials and Methods: Poloxamer 407 (P407) and poloxamer 188 (P188) were selected as carriers for the preparation of solid dispersion (SD) by 
the solvent evaporation method with different drug-polymer ratios. The prepared SDs were evaluated for the physical state, drug:carrier interactions 
by X-ray diffraction (XRD), infrared spectroscopy, differential scanning calorimetry, and scanning electron microscopy.
Results: From the dissolution studies, it is confirmed that all SDs showed increased dissolution rate when compared to pure amlodipine besylate. 
Among the two polymers used, P407 was found to be better than P188 in enhancing dissolution efficiency. The tablets were prepared using SD of 
amlodipine besylate containing P407 as a carrier. The results showed that P407 SD-based tablets gave a significantly higher release of amlodipine 
besylate when compared with control tablets. The infrared spectral studies showed that there was no significant interaction between amlodipine 
besylate and its formulation with different polymers used in the preparation of SDs. XRD studies revealed that the degree of crystallinity of amlodipine 
besylate reduced when the concentration of carriers increased, which reveals that the drug is in amorphous nature.
Conclusion: The combination of SD technology and using superdisintegrants in the formulation is a promising approach for preparing efficient, fast-
dissolving tablet of poorly water-soluble drugs, viz., amlodipine besylate.
Keywords: Amlodipine besylate, Calcium channel blocker, Fast-dissolving tablets, Poloxamer 407, Poloxamer 188, Solid dispersion, Superdisintergrants.
INTRODUCTION
Drugs which come under the Class II of BCS system are characterized 
by high membrane permeability and slow dissolution. The poor 
aqueous solubility of the drug and their low dissolution rate in the 
gastrointestinal fluids often lead to insufficient bioavailability and 
are one of the most difficult problems in pharmaceutical technology. 
It is estimated that more than 35% of the known drugs and more than 
25% of the newly discovered drugs possess such problems [1]. Solid 
dispersion (SD) technology can be used to enhance the dissolution 
rate of BCS Class II drugs, thereby improving their bioavailability. 
The enhancement of dissolution rate of the drug is important 
to attain suitable blood concentration for enhanced therapeutic 
effect as their dissolution rates are typically the rate-limiting step 
for bioavailability [2]. There are several methods employed for 
improving the solubility and dissolution rate of poorly aqueous 
soluble drugs, such as increasing the surface area by reducing the 
particle size, using surfactant systems, salt formation of the drug, 
prodrug approach, preparation of water-soluble complexes, and 
reducing the crystallinity of the drug. The most common method 
is decreasing the particle size by micronization technique. The 
technique is disadvantaged by the higher tendency of size reduced 
particles to stick together which leads to the formation of larger 
agglomerates which in turn leads to a decrease in effective surface 
area for dissolution. Nowadays, the most effective method to improve 
the dissolution rate is the use of SD technique [3]. The SDs are two-
component systems consisting of a hydrophilic carrier in which 
the drug is incorporated. The SD technology gives the possibility 
to reduce the drug particle size almost to a molecular level and 
increased wettability [4]. In addition to this, the crystalline drug is 
transformed to amorphous form, which can be beneficial, since the 
dissolution of an amorphous drug does not require energy to break 
up the crystalline lattice [5].
Another method to improve the dissolution of SD tablet is by the addition 
of superdisintegrants because they do not irritate the gastrointestinal 
tract and can be used in low amounts in the formulations [6]. Cross 
croscarmellose sodium, crospovidone, and sodium starch glycolate 
were used as superdisintegrants [7].
Amlodipine besylate is a calcium channel blocker which may be utilized in 
the management of hypertension, and it belongs to BCS Class II category. 
One of the biggest problems with this drug is its low solubility in biological 
fluids, which results into poor bioavailability after oral administration. 
Hence, SD technique can be used to improve the dissolution rate of the 
drug. The drug works by slowing down the rate at which calcium moves 
into heart, blood vessel walls, allowing better blood flow. Poloxamer 
407 (P407) and poloxamer 188 (P188) were used as the carriers for the 
preparation of SDs with amlodipine besylate [8]. Poloxamer is a synthetic 
block copolymer of ethylene oxide and propylene oxide and used widely 
in pharmaceutical preparations  [9].
MATERIALS AND METHODS
Materials
Amlodipine besylate, P407, and P188 were obtained from Orchid 
Chemicals & Pharmaceutics Ltd., Chennai. All other chemicals were of 
reagent grade and used without purification.
Preparation of SDs
Dichloromethane and ethanol were used as the solvent, and five 
different ratios of drug and carrier were used (1:1, 1:2, 1:3, 1:4, 1:5) 
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for preparing SDs of amlodipine besylate. In solvent evaporation 
method, respective quantity of carrier was dissolved in required 
volume of dichloromethane and ethanol in a conical flask to get a clear 
completely soluble solution using a magnetic stirrer. The weighed 
amount of amlodipine besylate was added to this solution carefully 
with constant stirring. Stirring was continued until the drug is 
completely dissolved in the polymeric solution. Then, the solvent was 
eliminated by evaporation at 40°C under vacuum. The mass obtained 
was dried in a desiccator, and the dried mass was pulverized and sifted 
through mesh no. 60 [10,11].
Drug content uniformity of SDs
The prepared SDs were tested for drug content uniformity. From each 
batch, the SDs equivalent to 20 mg of amlodipine besylate was taken 
and analyzed for drug content uniformity [12]. An accurately weighed 
quantity of amlodipine besylate SDs were taken in a 100 ml volumetric 
flask and dissolved in ethanol. The solutions were filtered, suitably 
diluted, and analyzed for drug content using a Shimadzu ultraviolet 
(UV)-visible spectrophotometer.
Infrared spectral analysis
Compatibility studies of amlodipine besylate and the polymers were 
carried out using Fourier transform infrared (FTIR) spectroscopy. FTIR 
spectra of the samples were obtained in the range of 4000-450/cm 
using a Perkin Elmer-FT-IR 8201 PC spectrophotometer by the KBr-disc 
method [13].
Powdered X-ray diffraction (XRD) studies
The powdered XRD patterns were recorded using X’Pert PRO-Analytical 
diffractometer with Cu as an anode material and operated at a 
voltage of 30 kV and a current of 15 mA. The samples were analyzed 
in 2q angle range of 0°-100° and the process parameters were set as 
follows - sampling width of 0.010° (2q) at a scanning speed of 1°/min 
and scan mode set is continuous [14].
Differential scanning calorimetry (DSC)
The DSC studies were carried out for pure drug and SDs using DSC-
60 (Shimadzu Corporation Japan) instrument. All standards were 
used to calibrate the DSC temperature, and the samples were sealed 
in aluminum pans and heated at a persistent rate of 5°C/min over a 
temperature range of 25-225°C. A static atmosphere was maintained by 
purging nitrogen gas at the flow rate of 50 ml/min [15].
Scanning electron microscopy (SEM)
The surface morphology of amlodipine besylate, P407, P188, and SDs 
was examined using SEM. The samples were mounted on a double-
faced adhesive tape and sputtered with thin gold palladium layer, and 
the surface morphology was analyzed with an SEM (Stereoscan 440, 
Leo Leica, Cambridge, UK) [16].
Dissolution studies
Dissolution studies of amlodipine besylate pure drug and SDs were 
performed according to the method prescribed in USP XXIV using 
apparatus 2. The paddle speed set at 50 rpm in 900 ml of phosphate 
buffer pH 6.8 and the temperature maintained at 37°C. SD powders 
equivalent to 10 mg of amlodipine besylate were taken for dissolution. 
Aliquots of 5 ml were withdrawn at selected time intervals (10, 20, 30, 
40, 60 and 90 minutes), and the samples are replaced with the fresh 
dissolution medium which is pre-warmed to 37°C. The quantity of drug 
released was estimated by measuring the absorbance at 239 nm by a 
UV spectroscopy nm [17-19].
Preparation of fast-dissolving tablets
The SD formulation which showed highest dissolution rate was 
formulated into tablets using various proportions of croscarmellose 
sodium, sodium starch glycolate, sodium, and crospovidone as 
superdisintegrants. The SDs equivalent to 10 mg of amlodipine besylate 
was taken, and the formulation of the prepared tablet is given in 
Table 1. The drug or its equivalent SDs was mixed with the excipients 
for 15 minutes by bottle method, before compression into tablets [20]. 
The tablet preparation process employed Cadmach 16 station rotary 
tablet making machine, and the compression force was adjusted for 
preparing the tablets having a hardness of 4-5 Kp.
Evaluation of fast-dissolving tablets
Uniformity of weight
Twenty tablets were weighed individually, and the average weight 
is compared with the individual tablet weights. As per the USP 
specifications, for tablets weighing 200 mg, the allowed weight 
variation deviation is 7.5%. The tablets meet the USP test if not more 
than two tablets are outside the limit and no tablet differs by more than 
twice the limit [21].
Tablet friability
The friability of the tablets was measured in Roche friabilator. 20 tablets 
were selected randomly, weighed and placed in friability apparatus, 
and subjected to 25 rpm for 4 minutes (100 revolutions). The tablets 
were wiped with a clean cloth and weighed again. The friability was 
calculated as the percentage loss should not exceed 1% [22].
Drug content
The drug content was determined by randomly selecting 30 tablets, 
and from these, ten tablets were individually assayed for drug content 
determination. The tablets were acceptable if the drug content of each 
of at least nine tablets were in the range of 85-115% of the stated 
amount of the drug. The 10th tablet should not contain <75% or >125% 
of the labeled content. If these conditions were not met, remaining 




The amlodipine besylate SDs were tested for drug content by UV 
method, and the drug content was found to be 97.5±3% w/w. All the 
SDs were uniform in drug content, and the results are shown in Table 2.
Infrared spectral analysis
The IR spectra of P407, P188, amlodipine besylate, and SDs are shown 
in Figs. 1 and 2. The spectrum of the pure drug shows strong absorption 
band at 3298.79/cm due to the stretching of the N-H group. The band 
at 3156.11/cm can be due to the stretching of aromatic C-H stretching. 
The strong absorption band at 2984.45/cm can be attributed to the 
Table 1: Master formula for the preparation of amlodipine besylate tablets
S. No. Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9
1 Amlodipine besylate P 407 1:5 Solid dispersion 60 60 60 60 60 60 60 60 60
2 Crospovidone 4 6 8 - - - - - -
3 Croscarmellose sodium - - - 8 10 12 - - -
4 Sodium starch glycolate - - - - - - 8 10 12
5 Magnesium stearate 2 2 2 2 2 2 2 2 2
6 Aerosil 2 2 2 2 2 2 2 2 2
7 Microcrystalline cellulose 132 130 128 128 126 124 128 126 124
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C-H stretching. The band at 1677.44/cm is for C=O bond and the band 
at 1493.94/cm is for the aromatic C=C bond. The strong absorption 
band at 1302.68/cm is due to C-N. The bands at 1205.85, 1122.19, and 
1095.52 are due to C-O. The spectrum of pure P407 and P188 shown 
in Figs. 1 and 2 was in good agreement with published data on the 
polymer. IR spectra of amlodipine besylate and its SDs are identical. 
The principle IR absorption peaks of amlodipine besylate SDs were 
observed and found to be identical with the spectra of amlodipine 
besylate pure drug. Thus, from the spectra, it was understood that there 
was no significant interaction between amlodipine besylate and the 
polymers used in the preparation of SDs.
Powdered XRD studies
The XRD measurements were conducted to clarify the physicochemical 
characteristics of all SDs. The XRD pattern of pure amlodipine besylate 
exhibited sharp, highly intense, and less diffused peaks indicating the 
crystalline nature of the pure drug. It showed sharp diffraction peaks 
at 2θ degree equal to 3.532, 10.214, 12.860, 14.293, 21.731, 24.030, 
26.618, and 31.829. The XRD of SDs showed a reduction in diffraction 
peak intensity at 2θ values at 2.320, 13.864, 14.391, 20.581, 25.283, 
and 29.436 indicating that the significant reduction in crystallinity of 
amlodipine besylate (Fig. 3).
DSC
The DSC analysis was done for pure amlodipine besylate and SDs 
of amlodipine besylate with carriers P407 and P188 which showed 
higher saturation solubility of the pure drug than the polymers 
used. The DSC thermogram of pure amlodipine besylate (Fig. 4a) 
showed a sharp endothermic peak which was ascribed to drug 
melting indicating its crystalline nature. The DSC curve of P407 
(Fig. 4b) and P188 (Fig. 4c) showed a sharp endothermic peak at 
58.9°C and 55.5°C corresponding to the melting point of P407 and 
P188. The endothermic peak corresponding to drug melting was 
shifted toward lower temperature in SDs. This could be attributed to 
higher polymer concentration and uniform distribution of the drug 
in polymer.
Table 2: Drug content uniformity of solid dispersions of 
amlodipine besylate
S. No. Solid dispersions(drug:carrier) % Drug content
1 P407 1:1 95.9±0.69
2 P407 1:2 97.6±0.24
3 P407 1:3 98.3±0.47
4 P407 1:4 99.2±0.58
5 P407 1:5 96.8±0.94
6 P188 1:1 95.6±0.30
7 P188 1:2 97.9±0.51
8 P188 1:3 99.1±0.18
9 P188 1:4 96.5±0.72
10 P188 1:5 98.8±0.32
P188: Poloxamer 188, P407: Poloxamer 407 
Fig. 1: Fourier transform infrared spectra of amlodipine besylate, 
poloxamer 188, and their solid dispersions
Fig. 2: Fourier transform infrared spectra of amlodipine besylate, 
poloxamer 407, and their solid dispersions
Table 3: Dissolution profile of amlodipine besylate from P407 SD at different drug: carrier ratios
Time in 
minutes
Percentage amlodipine besylate released from P407 SDs
Pure amlodipine besylate 1:1 1:2 1:3 1:4 1:5
10 6.38 43.54 47.49 53.64 55.49 63.35
20 8.97 49.28 50.25 55.71 68.43 77.85
30 15.82 56.81 53.32 63.46 71.53 85.56
40 18.39 63.35 68.20 74.91 86.2 98.31
60 22.74 75.89 79.59 85.27 93.57 100
90 26.54 81.34 88.27 93.94 100 100
SD: Solid dispersion, P407: Poloxamer 407
Table 4: Dissolution profile of amlodipine besylate from P188 SD at different drug:carrier ratios
Time in 
minutes
Percentage amlodipine besylate dissolved from P188 solid dispersions
Pure amlodipine besylate 1:1 1:2 1:3 1:4 1:5
10 6.38 38.54 41.45 48.67 51.31 58.26
20 8.97 42.93 48.29 58.74 64.38 69.57
30 15.82 51.08 56.84 61.95 69.55 75.38
40 18.39 56.89 64.69 68.29 77.79 82.11
60 22.74 61.05 69.28 76.15 81.22 85.59
90 26.54 68.70 76.75 83.27 88.19 91.25
SD: Solid dispersion, P188: Poloxamer 188
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SEM
The SEM analysis of pure drug in Fig. 5a showed crystalline in nature, 
and the drug particles were irregular in shape. The SDs of amlodipine 
besylate with P407 and P188 (Fig. 5b-e) showed a homogeneous 
dispersion indicating that the amlodipine besylate is dispersed 
uniformly in carrier matrices of SDs, assuming amorphous SD 
state [24,25].
Dissolution studies of SDs
For poorly water-soluble drugs, especially BCS Class II drugs, the 
improvement of drug solubility sometimes results in the enhancement 
of oral bioavailability [26-28]. The dissolution tests on pure amlodipine 
besylate and its SDs were carried out up to 90 minutes in phosphate 
buffer pH 6.8. Figs. 6 and 7 show the dissolution profile of pure drug 
powder and SDs with different carriers. The dissolution profile of pure 
drug shows slow dissolution rate with only 6.42% of the drug released 
in first 10 minutes. The total amount of drug released in 90 minutes 
was found to be 31.71% which revealed its high lipophilicity and its 
crystallinity (Table 3). Preparation of SD of the drug with P407 resulted 
in a significant increase in the dissolution rate compared to the pure 
drug. The enhancement of dissolution depended on the concentration 
of polymer in the SD [29-31]. Hence, the quantity of drug released 
in the first 10 min was increased gradually with increase in carrier 
concentration to reach 100% at 1:4 (drug to polymer ratio) which is 
much higher than that of pure amlodipine besylate or SDs containing 
lower proportions of P407.
For P188, preparation of SD with the drug resulted in gradual increase 
in the dissolution rate at low carrier concentration so that the amount 
of drug dissolved in the first 10 min was 38.54% in case of 1:1 (drug to 
Fig. 3: X-ray diffraction diffractogram of (a) pure amlodipine besylate, (b) poloxamer 407 (P407), (c) amlodipine besylate P407 solid 
dispersion (SD) 1:1, (d) amlodipine besylate P407 SD 1:3, (e) amlodipine besylate P407 SD 1:5, (f) poloxamer 188 (P188), (g) amlodipine 









Table 5: Dissolution profiles of fast-dissolving tablets
Time in 
minutes
Cumulative percentage drug released
Control tablet F1 F2 F3 F4 F5 F6 F7 F8 F9
10 6.42 47.63 53.84 61.85 46.96 49.47 55.75 41.93 43.87 50.25
20 9.35 56.71 61.63 69.43 56.84 55.58 61.39 48.56 50.84 59.01
30 11.78 65.50 69.21 76.80 59.82 67.83 73.23 56.07 58.38 68.82
40 16.25 72.54 74.90 83.47 65.37 71.95 79.64 68.18 69.82 74.91
60 18.86 81.07 83.97 91.05 73.08 79.48 87.42 74.95 78.04 82.73
90 31.71 88.68 93.28 98.71 81.37 85.06 92.62 79.91 87.32 90.84
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Fig. 6: Dissolution profile of amlodipine besylate from poloxamer 
407 solid dispersion at different drug:carrier ratios
Fig. 4: Differential scanning calorimetry curve of (a) pure amlodipine besylate, (b) poloxamer 407 (P407), (c) poloxamer 188 (P188), 




Fig. 5: Scanning electron microscopy microphotograph of 
(a) pure drug amlodipine besylate, (b) poloxamer 407 (P407) 
polymer, (c) amlodipine besylate P407 solid dispersion (SD) 1:5, 





polymer ratios). This amount increased significantly increased in the 
case of 1:2, 1:3, 1:4 and reached 91.25% of the labeled amount in 1:5 
ratio (Table 4). This result shows the need for higher concentrations of 
the polymer to convert it into amorphous form and to achieve better 
dissolution parameters.
Characterization of tablets
The formulated tablets were found to be uniform in weight, and the 
weight variation was within the limit of 7.5%. It was found that the 
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friability of all tablet formulations was <1%. The result shows resistant 
to loss of weight indicates the tablet ability to withstand abrasion in 
handling, packaging, and shipment. The hardness of tablet ranged from 
3.5 to 4 kg/cm2. The percent drug content was found to be 100±5%.
In vitro study of tablets
The results reveal that the disintegration time of the tablets decreased 
with increase in the amount of superdisintegrants used in the tablet 
formulation. It shows that increase in the level of superdisintegrants 
(croscarmellose sodium, sodium starch glycolate, and crospovidone) 
had a positive effect on the disintegration time of fast-superdissolving 
tablets.
The dissolution behavior of various formulations and the control tablets 
is depicted in Figs. 8-10. The drug release from the tablet formulations 
followed the order: F3 > F2 > F6 > F9 > F1 > F8 > F5 > F4 > F7. The pattern 
gives an idea about the effect of superdisintegrants in drug-release 
profile of fast-dissolving tablets (Table 5). The in vitro drug dissolution 
profile of fast dissolving tablets was found to be increased with increase 
in superdisintegrant level. The highest drug release was observed in 
crospovidone followed by croscarmellose sodium and sodium starch 
glycolate. The fast-dissolving tablets containing crospovidone (4%) 
showed the highest drug release (98.71%). The control tablets were 
prepared with crospovidone (4%) with other ingredients using pure 
amlodipine besylate, and the dissolution profile is compared with the 
formulation containing SD of drug (Figs. 8-10).
CONCLUSION
In the present study, the SDs of amlodipine besylate were prepared with 
P188 and P407 with the aim of enhanced dissolution rate. The fastest 
drug release was obtained from amlodipine besylate P407 SD in the 
ratio of 1:5 prepared by solvent evaporation method. The preparation 
of fast-dissolving tablets using the SD of amlodipine besylate is a unique 
technique by which the dissolution rate of the drug can be increased 
which is the most challenging aspect of drug delivery. The method 
employed was found to be economical and industrially feasible. Thus, 
it can be concluded that combination of SD and superdisintegrants 
in the formulation is a promising approach for preparing efficient, 
fast dissolving tablet of poorly water-soluble drugs, viz., amlodipine 
besylate.
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